188 related articles for article (PubMed ID: 37947131)
1. Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.
Prakash S; Mares AC; Porres-Aguilar M; Mukherjee D; Barnes GD
Vasc Med; 2024 Feb; 29(1):85-92. PubMed ID: 37947131
[TBL] [Abstract][Full Text] [Related]
2. Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis.
Presume J; Ferreira J; Ribeiras R; Mendes M
J Thromb Haemost; 2022 Dec; 20(12):2930-2938. PubMed ID: 36128769
[TBL] [Abstract][Full Text] [Related]
3. Factor XI inhibitors: what should clinicians know.
Pandey A; Verma R; Eikelboom J; Verma S
Curr Opin Cardiol; 2023 Mar; 38(2):88-93. PubMed ID: 36718618
[TBL] [Abstract][Full Text] [Related]
4. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.
Chan NC; Weitz JI
Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):1755-1763. PubMed ID: 37650326
[TBL] [Abstract][Full Text] [Related]
5. A new strategy for anticoagulation: The factor XI inhibitors.
Vedovati MC; Becattini C; Agnelli G
Eur J Intern Med; 2023 Oct; 116():8-15. PubMed ID: 37544845
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction.
Wang TF; Khorana AA; Agnelli G; Bloomfield D; Bonaca MP; Büller HR; Connors JM; Goto S; Jing ZC; Kakkar AK; Khder Y; Raskob GE; Soff GA; Verhamme P; Weitz JI; Carrier M
Oncologist; 2023 Jul; 28(7):555-564. PubMed ID: 37171998
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and Clinical Development of Factor XI Inhibitors.
Greco A; Laudani C; Spagnolo M; Agnello F; Faro DC; Finocchiaro S; Legnazzi M; Mauro MS; Mazzone PM; Occhipinti G; Rochira C; Scalia L; Capodanno D
Circulation; 2023 Mar; 147(11):897-913. PubMed ID: 36913497
[TBL] [Abstract][Full Text] [Related]
8. Targeting factor XI and factor XIa to prevent thrombosis.
Gailani D; Gruber A
Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
[TBL] [Abstract][Full Text] [Related]
9. Factor XI antisense oligonucleotide for prevention of venous thrombosis.
Büller HR; Bethune C; Bhanot S; Gailani D; Monia BP; Raskob GE; Segers A; Verhamme P; Weitz JI;
N Engl J Med; 2015 Jan; 372(3):232-40. PubMed ID: 25482425
[TBL] [Abstract][Full Text] [Related]
10. Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives.
Poenou G; Dumitru Dumitru T; Lafaie L; Mismetti V; Heestermans M; Bertoletti L
Vasc Health Risk Manag; 2022; 18():359-373. PubMed ID: 35707632
[TBL] [Abstract][Full Text] [Related]
11. Factor XI, a potential target for anticoagulation therapy for venous thromboembolism.
Li T; Liu J; Wu W
Front Cardiovasc Med; 2022; 9():975767. PubMed ID: 36386334
[TBL] [Abstract][Full Text] [Related]
12. Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials.
Daghlas I; Gill D
Eur J Neurol; 2023 Jul; 30(7):2112-2116. PubMed ID: 37038320
[TBL] [Abstract][Full Text] [Related]
13. A review of emerging factor XI inhibitors.
Elsheikh S; Tidbury N; Lip GYH
Expert Opin Emerg Drugs; 2023 Mar; 28(1):43-53. PubMed ID: 36927160
[TBL] [Abstract][Full Text] [Related]
14. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Robertson L; Yeoh SE; Ramli A
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants and venous thromboembolism.
Franchini M; Mannucci PM
Eur Respir Rev; 2016 Sep; 25(141):295-302. PubMed ID: 27581829
[TBL] [Abstract][Full Text] [Related]
16. [Evidence-based research and prognosis of novel coagulation factor Ⅺ inhibitors in venous thromboembolism].
Liu D; Tian H; Zhai ZG
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Sep; 45(9):925-930. PubMed ID: 36097930
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in understanding, diagnosing and treating venous thrombosis.
Chan NC; Weitz JI
F1000Res; 2020; 9():. PubMed ID: 33082930
[TBL] [Abstract][Full Text] [Related]
18. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.
Vasanthamohan L; Boonyawat K; Chai-Adisaksopha C; Crowther M
J Thromb Haemost; 2018 Jul; 16(7):1288-1295. PubMed ID: 29772108
[TBL] [Abstract][Full Text] [Related]
19. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Wang X; Ma Y; Hui X; Li M; Li J; Tian J; Wang Q; Yan P; Li J; Xie P; Yang K; Yao L
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010956. PubMed ID: 37058421
[TBL] [Abstract][Full Text] [Related]
20. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
